Home » Stocks » Aridis Pharmaceuticals

Aridis Pharmaceuticals Inc. (ARDS)

Stock Price: $7.77 USD 0.12 (1.57%)
Updated Oct 23, 2020 4:00 PM EDT - Market closed

Stock Price Chart

Key Info

Market Cap 78.15M
Revenue (ttm) 1,000,000
Net Income (ttm) -23.96M
Shares Out 10.06M
EPS (ttm) -2.70
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Oct 23, 2020
Last Price $7.77
Previous Close $7.65
Change ($) 0.12
Change (%) 1.57%
Day's Open 8.04
Day's Range 7.68 - 8.34
Day's Volume 10,221
52-Week Range 3.80 - 10.18

More Stats

Market Cap 78.15M
Enterprise Value 67.05M
Earnings Date (est) Nov 11, 2020
Ex-Dividend Date n/a
Shares Outstanding 10.06M
Float 5.86M
EPS (basic) -2.69
EPS (diluted) -2.70
FCF / Share -0.27
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 59,659
Short Ratio 5.11
Short % of Float 1.02%
Beta 0.06
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio 78.15
PB Ratio 5.40
Revenue 1,000,000
Operating Income -23.87M
Net Income -23.96M
Free Cash Flow -2.42M
Net Cash 11.10M
Net Cash / Share 1.10
Gross Margin -2,306.10%
Operating Margin -2,387.00%
Profit Margin -2,395.90%
FCF Margin -242.10%
ROA -87.79%
ROE -1,000.79%
ROIC 325.70%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (5)

Buy 5
Overweight 0
Hold 0
Underweight 0
Sell 0

Analyst Consensus: Buy

Price Target

(139.38% upside)
Current: $7.77
Target: 18.60
*Average 12-month price target from 5 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Revenue Growth-62.93%220.58%-62.1%-
Gross Profit1.022.760.860.34
Operating Income-29.09-24.12-19.74-7.88
Net Income-29.68-22.11-24.66-8.42
Shares Outstanding8.463.150.170.17
Earnings Per Share-3.51-7.45-148.20-50.62
Operating Cash Flow-8.16-24.27-17.56-6.09
Capital Expenditures-0.17-0.68-0.70-0.02
Free Cash Flow-8.33-24.95-18.26-6.11
Cash & Equivalents20.9024.2425.1022.29
Net Cash / Debt20.9024.2425.1022.29
Book Value3.6426.31-62.77-45.12
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Aridis Pharmaceuticals Inc.
Country United States
Employees 25
CEO Vu L. Truong

Stock Information

Ticker Symbol ARDS
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: ARDS
IPO Date August 10, 2018


Aridis Pharmaceuticals, a late-stage biopharmaceutical company, focuses on the discovery and development of targeted immunotherapy using fully human monoclonal antibodies (mAb) to treat life-threatening infections. Its lead product candidate is AR-301, a fully human mAb of immunoglobulin 1 (IgG1) that is in Phase III pivotal trials for the treatment of lung infections resulting from S. aureus alphatoxin. The company is also developing AR-105, a fully human IgG1 mAb, which is in Phase II trials to target gram-negative bacteria P. aeruginosa; AR-101, a human IgM mAb, which is in Phase II clinical trials for the treatment of hospital-acquired pneumonia (HAP)and ventilator-associated pneumonia (VAP) caused by P. aeruginosa serotype O11; AR-401 that is in preclinical stage to treat infections caused by Acinetobacter baumannii; AR-201, a fully human IgG1 mAb preclinical program for respiratory syncytial virus; and AR-501, an anti-infective therapy, which is in Phase I/IIa clinical trial to manage chronic lung infections in cystic fibrosis patients and acute pneumonia in HAP and VAP patients. Aridis Pharmaceuticals, Inc. was founded in 2003 and is headquartered in San Jose, California.